×
Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 3rd, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

Machine Learning Could Benefit Rheumatoid Arthritis Treatment with Sarilumab
https://www.hcplive.com/view/machine-learning-benefit-rheumatoid-arthritis-treatment-sarilumab

Nov 2nd, 2020 - As interleukin receptor (IL) inhibitors, the monoclonal antibody drug class has come to revolutionize fields of inflammatory disease care, though the utility and resourcing of such promising agents is yet to be fully refined. Namely, clinicians can stand to benefit from more biomarkers, more indications by which monoclonal antibodies are most impactful.

ACR 2020 Frequently Asked Questions
https://www.rheumatology.org/Annual-Meeting/Resources

Sep 6th, 2020 - Please refer to the Frequently Asked Questions (FAQs) below for more information on the all-virtual ACR Convergence 2020. We will share more details as they become available in the coming weeks and months.

ACR 2020 Permissions and Reprints
https://www.rheumatology.org/Annual-Meeting/Abstracts/Permissions-and-Reprints

Sep 6th, 2020 - ACR Convergence, the ACR's annual meeting, is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, ...

ACR 2020 General Meeting Information
https://www.rheumatology.org/Annual-Meeting/Resources/General-Meeting-Information

ACR Convergence, the American College of Rheumatology’s 2020 annual meeting will be in Washington, D.C. November 6 - 11.

ACR/ARHP 2020 American College of Rheumatology Annual Meeting 2020
https://acr-arhp2020.org/

American College of Rheumatology Annual Meeting 2020 06-11 November 2020 Washington DC.

ACR 2020 Abstract Embargo Policies
https://www.rheumatology.org/Annual-Meeting/Abstracts/Embargo-Policies

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new ...

ACR 2020 Online Program
https://plan.core-apps.com/tristar_acr20/customScreen/aboutACR20Program

The Online Program is your source for educational content and program information for the 2020 ACR/ARP Annual Meeting. Look for topics of interest, bookmark sessions, and/or create a customized itinerary. Use the navigation menu to browse sessions, faculty, abstracts, and other meeting content. You can also use the advanced search tool to find sessions.

ACR 2020 Contacts
https://www.rheumatology.org/Annual-Meeting/Resources/Annual-Meeting-Contacts

Registration and Hotels, Education, Abstracts, Exhibits, Press

ACR 2020 Abstracts
https://www.rheumatology.org/Annual-Meeting/Abstracts

Submission, presentation, permission/reprints, embargo, ACR Convergence Awards

ACR 2020 Program
https://www.rheumatology.org/Annual-Meeting/Program

The program has hundreds of sessions to educate professionals in every segment of rheumatology.

ACR 2020 Image Competition Guidelines & Procedures PDF
https://www.rheumatology.org/Portals/0/Files/Image-Competition-Guidelines.pdf

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals(ARP) invite you to submit a case-based image and take advantage of the opportunity to have your work peer-reviewed by experts in the field. If accepted, your image will be digitally displayed in the distinguished international venue of ACR Convergence 2020 and be added to the ACR Rheumatology Image Libr...

ACR 2020 Image Competition
https://www.rheumatology.org/Annual-Meeting/Program/Image-Competition

Call for Images, Submission Eligibility, Timeline, Permissions

https://www.the-rheumatologist.org/article/diversity-from-concepts-to-outcomes/
Diversity: From Concepts to Outcomes
The Rheumatologist; Bernstein S.

Nov 11th, 2020 - In 2020, terms like unconscious bias, diversity and inclusivity are buzzwords in rheumatology as well as throughout American society. The COVID-19 pandemic revealed stark disparities in healthcare outcomes for rheumatic disease patients of racial and ethnic minorities, including new research that shows Black and Latinx patients have a higher risk of hospitalization and threefold increased odds ...

PROs: Which Are Important to Patients and How Successfully Are They Integrated Into Clinical Care?
https://www.ajmc.com/view/pros-which-are-important-to-patients-and-how-successfully-are-they-integrated-into-clinical-care
The American Journal of Managed Care; Joszt L.

Nov 11th, 2020 - Although patient-reported outcomes (PROs) are increasingly being used to understand treatment effectiveness, there is still a lot unknown about what measures patients find most important. Two abstracts presented at the American College of Rheumatology’s annual meeting evaluated PROs in rheumatology and how PRO measures can be used in clinical care.

ACR Convergence 2020: Progress Toward COVID-19 Vaccines
https://www.the-rheumatologist.org/article/acr-convergence-2020-progress-toward-covid-19-vaccines/
The Rheumatologist; Hickman RJ.

Nov 10th, 2020 - A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across the field, reported on data concerning his lab’s con...

Inaugural ACR Distinguished Global Public Health Award Presented to Dr. Fauci
https://www.the-rheumatologist.org/article/inaugural-acr-distinguished-global-public-health-award-presented-to-dr-fauci/
The Rheumatologist; Bernstein S.

Nov 10th, 2020 - At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, ACR President Ellen M. Gravallese, MD, chief of the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital, Boston, presented the inaugural ACR Distinguished Global Public Health Award to Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), an ACR Master an...

COVID-19 antimalarial shortages affected rheumatology patients’ physical, mental health
https://www.healio.com/news/rheumatology/20201107/covid19-antimalarial-shortages-affected-rheumatology-patients-physical-mental-health

Nov 8th, 2020 - Antimalarial drug shortages due to COVID-19 affected more rheumatology patients in African and East Asian regions than those in the Americas and Europe, noted data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey.

Comparative Performances of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes
https://www.rheumatologyadvisor.com/home/conference-highlights/acr-convergence-2020/comparative-performance-of-sglt2-inhibitors-in-reducing-gout-in-t2d/

Nov 8th, 2020 - Among patients with type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibitors dapagliflozin and empagliflozin vs canagliflozin show greater benefit in reducing gout, according to research results presented at the American College of Rheumatology (ACR) Convergence 2020, held virtually from November 5 to 9, 2020.

Under Pressure: An Update on Pulmonary Hypertension
https://www.the-rheumatologist.org/article/under-pressure-an-update-on-pulmonary-hypertension/
The Rheumatologist; Liebowitz J.

Nov 8th, 2020 - In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George Washington School of Medicine &...

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
https://www.the-rheumatologist.org/article/acr-convergence-2020-study-data-for-lupus-rheumatoid-arthritis/
The Rheumatologist; Hickman RJ.

Nov 8th, 2020 - At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate.

COVID-19 Infection Rates Low in People with Rheumatic Diseases, Most Report Mild Illness
https://www.newswise.com/coronavirus/covid-19-infection-rates-low-in-people-with-rheumatic-diseases-most-report-mild-illness/?article_id=740879

Nov 7th, 2020 - ATLANTA — A new study shows that the COVID-19 infection incidence has been low in people with rheumatic diseases, and most of those infected experience a mild course of illness. Additionally, fatalities have been low among rheumatic disease patients infected with COVID-19. Details of this research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting (ABSTRACT ...

ACR RA guidelines ‘push the needle away’ from glucocorticoids as primary option
https://www.healio.com/news/rheumatology/20201109/acr-ra-guidelines-push-the-needle-away-from-glucocorticoids-as-primary-option

Nov 7th, 2020 - Glucocorticoids should no longer be the “default” option for many patients with rheumatoid arthritis, according to authors of a new recommendation document presented at ACR Convergence 2020.

Warfarin linked to greater hip, knee replacement risk
https://www.healio.com/news/rheumatology/20201108/warfarin-linked-to-greater-hip-knee-replacement-risk

Nov 7th, 2020 - Treatment with warfarin is associated with a significantly greater risk for hip or knee replacement compared with direct oral anticoagulants, according to a speaker at ACR Convergence.

Osteoporosis 'largely ignored' in older men
https://www.healio.com/news/rheumatology/20201110/osteoporosis-largely-ignored-in-older-men

Nov 6th, 2020 - Less than 3% of older men who had experienced an osteoporosis-related fracture had been properly diagnosed and treated, according to findings presented at ACR Convergence 2020.

Slow Taper off Antimalarial Is Best to Avoid Lupus Flare During Remission
https://www.medscape.com/viewarticle/941743

Nov 29th, 2020 - Slowly tapering off – or remaining on – antimalarial medications can help prevent disease flare in patients with systemic lupus erythematosus (SLE) who've achieved clinical remission for at least a year, according to a new study that was presented at the virtual annual meeting of the American College of Rheumatology. "Except in the setting of toxicity, cessation of antimalarial medication in pa...

RA Remission? Stop Methotrexate, Keep Etanercept
https://www.medscape.com/viewarticle/941555

Nov 23rd, 2020 - In patients with RA whose disease is well controlled by methotrexate combined with etanercept, withdrawal of methotrexate led to long-term outcomes that were nearly as good as continuation of combination therapy. The finding comes from the randomized, controlled SEAM-RA trial that sought to address weaknesses of previous studies. It included a long lead-in time with stringent criteria to ensure...

Gout Clinical Practice Guidelines (ACR, 2020)
https://reference.medscape.com/viewarticle/941449

Nov 23rd, 2020 - Guidelines for managing gout were published in June 2020 by the American College of Rheumatology (ACR).[1] Indications for Pharmacologic Urate-Lowering Therapy (ULT)   Initiating ULT is strongly recommended for gout patients with ≥1 subcutaneous tophi, evidence of radiographic damage (any modality) attributable to gout, or frequent gout flares (≥2 annually). Initiating ULT is conditionally reco...

Debate: After Methotrexate Failure, Is JAK Inhibitor or Biologic Next?
https://www.medscape.com/viewarticle/941432

Nov 22nd, 2020 - What is the next step in treatment after a person with rheumatoid arthritis fails to adequately respond to methotrexate — a Janus kinase (JAK) inhibitor or a biologic? That was the focus of a lively debate at the virtual annual meeting of the American College of Rheumatology. Vibeke Strand, MD, argued that JAK inhibitors offer the distinct advantage of a faster clinical response than biologics,...

Children With Kawasaki Disease Need Long-Term Surveillance for Heart Disease
https://www.medscape.com/viewarticle/940775

Nov 12th, 2020 - NEW YORK (Reuters Health) - Children with Kawasaki disease remain at an increased risk for heart problems more than 10 years after they leave the hospital, according to a new study. "The results justify additional follow up and surveillance for cardiovascular disease and cardiovascular disease risk factors, such as obesity, high blood pressure and high cholesterol, in Kawasaki disease survivors...

JIA Guideline Calls for Earlier Use of Targeted Therapies
https://www.staging.medscape.com/viewarticle/940926

Nov 12th, 2020 - A draft guideline for the management of patients with juvenile idiopathic arthritis reflects changes in therapy away from reliance on NSAIDs and glucocorticoids and toward earlier introduction of biologic disease-modifying antirheumatic drugs (DMARDs). The guideline, described in an oral session during the virtual annual meeting of the American College of Rheumatology, contains weighted recomme...

Methotrexate and Hydroxychloroquine Split on Cardiovascular Outcomes in RA
https://www.medscape.com/viewarticle/940971

Nov 12th, 2020 - No significant differences in major adverse cardiovascular events (MACE) emerged between methotrexate and hydroxychloroquine (HCQ) treatment in a comparison of adults 65 years or older with rheumatoid arthritis (RA). However, researchers reported some elevation in risk for stroke in the methotrexate group and for myocardial infarction (MI) and heart failure in the HCQ group. The primary outcome...

Sjögren's Symptom Clusters May Identify Treatment Options
https://www.medscape.com/viewarticle/940960

Nov 12th, 2020 - Patients with Sjögren's syndrome can be categorized into four distinct symptom clusters — independent of age, sex, and some disease manifestations — that may both improve symptom relief and aid in the development of targeted therapies, investigators reported. Analysis of data from a survey conducted by the Sjögren's Foundation identified four symptom clusters based on the grouping of five commo...

JIA Guideline Calls for Earlier Use of Targeted Therapies
https://www.medscape.com/viewarticle/940926

Nov 12th, 2020 - A draft guideline for the management of patients with juvenile idiopathic arthritis reflects changes in therapy away from reliance on NSAIDs and glucocorticoids and toward earlier introduction of biologic disease-modifying antirheumatic drugs (DMARDs). The guideline, described in an oral session during the virtual annual meeting of the American College of Rheumatology, contains weighted recomme...

'Reassuring' Data on Cardiac Toxicity With Hydroxychloroquine in RA, Lupus
https://www.staging.medscape.com/viewarticle/940635

Nov 9th, 2020 - NEW YORK (Reuters Health) - Hydroxychloroquine has no significant impact on heart rhythm in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), according to two studies featured at a press briefing at ACR Convergence, the 2020 annual virtual meeting of the American College of Rheumatology. "Our findings really do reinforce the fact that hydroxychloroquine is a safe an...

Treatment Sequence With Romosozumab Influences Osteoporosis Outcomes
https://www.staging.medscape.com/viewarticle/940675

Nov 9th, 2020 - Timing is everything when it comes to the use of the anabolic agent romosozumab (Evenity) for the treatment of advanced osteoporosis, a review of clinical trials suggests. In four studies with treatment sequences in which romosozumab was administered either before or following the use of an antiresorptive agent, initial treatment with 1 year of romosozumab produced substantial bone mineral dens...

'Reassuring' Data on Cardiac Toxicity With Hydroxychloroquine in RA, Lupus
https://www.medscape.com/viewarticle/940635

Nov 9th, 2020 - NEW YORK (Reuters Health) - Hydroxychloroquine has no significant impact on heart rhythm in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), according to two studies featured at a press briefing at ACR Convergence, the 2020 annual virtual meeting of the American College of Rheumatology. "Our findings really do reinforce the fact that hydroxychloroquine is a safe an...

Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
https://acrabstracts.org/abstract/characterizing-morphea-subsets-using-a-multi-center-prospective-cross-sectional-analysis/
Jane Zhu, Smriti Prasad, Kaila Schollaert-Fitch et. al.

Nov 9th, 2020 - Background/Purpose: Morphea, or localized scleroderma, is an inflammatory condition of the skin and soft tissue that results in excessive collagen deposition, often producing permanent functional and cosmetic impairment. Morphea affects both adults and children, with approximately 50% of patients having childhood onset disease1,2. Numerous classification schemes for morphea exist, but none have...

Curdlan-induced Villous Permeability, Luminal Pathobiont Translocation to the Ileal Crypts, Ileitis and Arthritis Are Mitigated by Clostridia in Colonised Germ-free SKG Mice
https://acrabstracts.org/abstract/curdlan-induced-villous-permeability-luminal-pathobiont-translocation-to-the-ileal-crypts-ileitis-and-arthritis-are-mitigated-by-clostridia-in-colonised-germ-free-skg-mice/
Anne-Sophie Bergot, Rabina Giri, Amy Cameron et. al.

Nov 9th, 2020 - Background/Purpose: IL-23 dependent spondylitis, arthritis and inflammatory bowel disease (IBD) recapitulate human spondyloarthropathy (SpA) in 1,3 beta glucan (curdlan)-treated SKG mice. Human SpA and SKG mice have fecal dysbiosis, with increased Bacteroidaceae and Porphyromonadaceae. In SKG mice, anti-IL-23 supports homeostatic bacteria, including Clostridiaceae, which produce the short chain...

Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
https://acrabstracts.org/abstract/clinically-important-improvements-in-patients-with-osteoarthritis-treated-with-subcutaneous-tanezumab-results-from-a-56-week-randomized-nsaid-controlled-study/
David Hunter, Tuhina Neogi, Melvin Churchill et. al.

Nov 9th, 2020 - Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in patients (pts) for whom use of other analgesics was ineffective or not appropriate in a randomized NSAID-controlled global long-term safety study (NCT02528188). The current analysis examines the effect of tanezum...

Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
https://acrabstracts.org/abstract/comparison-of-two-rituximab-regimens-for-induction-of-remission-in-antineutrophil-cytoplasm-antibody-associated-vasculitis-systematic-review-and-meta-analysis/
Valerie Benard, Cynthia Farhat, Melissa Zarandi-Nowroozi et. al.

Nov 9th, 2020 - Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or rituximab (RTX) in combination with glucocorticoids. Different RTX regimens for induction of remission are available: the 4-dose AAV regimen at doses of 375 mg/m2 I....

Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients
https://acrabstracts.org/abstract/circulating-biomolecules-as-potential-biomarkers-of-early-and-establishedresponse-to-tnfi-therapy-in-rheumatoid-arthritis-patients/
Chary Lopez-Pedrera, Maria Luque-Tevar, Carlos Pérez-Sánchez et. al.

Nov 9th, 2020 - Background/Purpose: To evaluate changes produced in circulating inflammatory mediators and their regulatory miRNAs in RA patients after 3 and 6 months of treatment with TNF-α inhibitors (TNFi), in order to identify biomarkers of clinical efficacy and potential predictors of therapeutic response to TNFi therapies. Methods: In a prospective RA cohort multicenter study, serum from125 RA patients w...

Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine ...
https://acrabstracts.org/abstract/cutaneous-side-effects-of-hydroxychloroquine-in-rheumatic-diseases-combination-of-traditional-multivariate-analysis-for-risk-factors-andclassification-model-development-usin/
Sandeep Surendran, Mithun CB, Arun Tiwari et. al.

Nov 9th, 2020 - Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning tools have emerged as a promising option for predicting various outcomes. The aim of our study was to use “traditional” multivariate analysis along with novel machine learning (ML) methodology to anal...

Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthri...
https://acrabstracts.org/abstract/comparison-of-work-productivity-outcomes-between-chronic-back-pain-patients-with-and-without-a-diagnosis-of-axial-spondyloarthritis-after-2-year-protocolised-follow-up-data-from-the-spondyloarthritis/
Anne Boel, Miranda van Lunteren, Karen Fagerli et. al.

Nov 9th, 2020 - Background/Purpose: The aim of this study was to compare work-productivity and activity impairment outcomes after two-year follow-up between chronic back pain (CBP) patients with and without an axSpA diagnosis Methods: Patients over 16 years of age referred to the rheumatology outpatient clinic with chronic back pain (≥ 3 months < 2 years) starting before the age of 45, suspected of axSpA were ...

Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
https://acrabstracts.org/abstract/comparative-effectiveness-of-secukinumab-adalimumab-and-other-tumor-necrosis-factor-inhibitors-in-the-treatment-of-axial-spondyloarthritis/
Loïc Choquette Sauvageau, Denis Choquette, Louis Bessette et. al.

Nov 9th, 2020 - Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing. Secukinumab is an agent targetting Il-17. The aim of our analysis is to compare the effectiveness of the most frequently used biologic in axSpA since the marketing of secukinumab in all, fir...

Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases
https://acrabstracts.org/abstract/characterization-of-cytokine-chemokine-profile-in-patient-derived-m1-m2-macrophages-to-identify-biomarkers-for-genetically-defined-systemic-autoinflammatory-diseases/
Farzana Bhuyan, Adriana Almeida de Jesus, Kim Johnson et. al.

Nov 9th, 2020 - Background/Purpose: Genetic mutations in key regulatory molecules of the innate immune system cause autoinflammatory diseases through propagation of hyperinflammatory responses. Monocytes/ macrophages regulate inflammatory processes during infection and homeostasis by secreting a wide range of cytokines and chemokines that control recruitment and migration of immune cells to inflamed tissue, an...

Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study
https://acrabstracts.org/abstract/clinical-characteristics-of-importance-to-outcome-in-patients-with-axial-spondyloarthritis-a-prospective-cohort-study/
Rikke Asmussen Andreasen, Xenofon Baraliakos, Lars Erik Kristensen et. al.

Nov 9th, 2020 - Background/Purpose: Despite better control of inflammation, many patients with axial spondyloarthritis (axSpA) still report pain, although they could be in remission. This suggests that in these patients chronic pain may prompt central sensitization. Our objective was to explore the prognostic value of the painDETECT questionnaire (PDQ) in relation to treatment outcomes in axSpA Methods: AxSpA ...

Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with...
https://acrabstracts.org/abstract/comparison-of-nation-wide-epidemical-study-on-2009-and-that-on-2019-revealed-that-improvement-of-disease-severity-and-mortality-rate-may-come-from-progress-of-proficient-management-in-patients-with-re/
Jun Shimizu, Yoshihisa Yamano, Kimito Kawahata2 and Noboru Suzuki et. al.

Nov 9th, 2020 - Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we found a strong inverse relationship between ear and airway involvement, suggesting that the two major clinical symptoms of RP occurred in a mutually exclusive manner (Arthritis Rheumatol. 2018). When we divided the patien...

Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Dat...
https://acrabstracts.org/abstract/associations-between-patient-reported-outcomes-and-impairments-of-work-and-activity-in-patients-with-rheumatoid-arthritis-who-achieved-clinical-remission-retrospective-analysis-using-the-iorra-databa/
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue et. al.

Nov 9th, 2020 - Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily activity are relevant burdens for patients with RA. However, detailed analyses are rarely performed. For exploring a better strategy aiming at less burden beyond Treat-to-Target strategy, it is esse...